BlackRock Institutional Trust’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BlackRock Institutional Trust’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.19M	Buy	651,615 +38,494	+6%	+$231K	﹤0.01%	2885
2016 Q3	$4.75M	Sell	613,121 -13,751	-2%	-$92.6K	﹤0.01%	2714
2016 Q2	$3.51M	Sell	626,872 -5,305	-0.8%	-$33.9K	﹤0.01%	2831
2016 Q1	$3.4M	Buy	632,177 +1,753	+0.3%	+$10.2K	﹤0.01%	2826
2015 Q4	$5.49M	Buy	630,424 +23,783	+4%	+$201K	﹤0.01%	2672
2015 Q3	$5.09M	Sell	606,641 -40,865	-6%	-$651K	﹤0.01%	2708
2015 Q2	$11.4M	Buy	647,506 +207,351	+47%	+$2.66M	﹤0.01%	2317
2015 Q1	$5.09M	Buy	440,155 +68,340	+18%	+$791K	﹤0.01%	2749
2014 Q4	$3.74M	Buy	371,815 +82,918	+29%	+$420K	﹤0.01%	2842
2014 Q3	$1.31M	Buy	288,897 +41,610	+17%	+$223K	﹤0.01%	3233
2014 Q2	$1.67M	Buy	247,287 +62,234	+34%	+$469K	﹤0.01%	3269
2014 Q1	$2.37M	Buy	185,053 +57,124	+45%	+$632K	﹤0.01%	3093
2013 Q4	$1.04M	Buy	+127,929	New	+$1.13M	﹤0.01%	3385

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock Institutional Trust's SRNE Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Sorrento Therapeutics, Inc. (SRNE) stake by 6.3% in Q4 2016, buying an estimated $231K and bringing the position to 651,615 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

BlackRock Institutional Trust first reported a position in SRNE in Q4 2013 and has held it in 13 quarters since. The position peaked at $11.4M in Q2 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

BlackRock Institutional Trust held 651,615 shares of Sorrento Therapeutics, Inc. worth $3.19M as of Q4 2016.
BlackRock Institutional Trust bought 38,494 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $231K.
Sorrento Therapeutics, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2885 holding.
BlackRock Institutional Trust first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and has held it in 13 quarters since.
BlackRock Institutional Trust's Sorrento Therapeutics, Inc. position peaked at $11.4M in Q2 2015.
68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.